OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OCULAR SURFACE DISEASE

1 . A pharmaceutical composition for topical administration to an eye, the composition comprising betamethasone sodium phosphate at a concentration of 0.01% w/w to 0.05% w/w; mycophenolic acid at a concentration of 0.05% w/w to 0.50% w/w; and a pharmaceutically acceptable carrier for topical administration to the eye.

2 . The pharmaceutical composition of claim 1 , further comprising a glycosaminoglycan.

3 . The pharmaceutical composition of claim 2 , wherein the glycosaminoglycan comprises chondroitin sulfate.

4 . The pharmaceutical composition of claim 3 , wherein the chondroitin sulfate is at a concentration of 0.1% w/w to 5.0% w/w.

5 . The pharmaceutical composition of claim 3 , further comprising a deturgescent agent.

6 . The pharmaceutical composition of claim 5 , wherein the deturgescent agent comprises dextran.

7 . The pharmaceutical composition of claim 6 , wherein the dextran is at a concentration of 0.1% w/w to 5.0% w/w.

8 . The pharmaceutical composition of claim 1 , wherein the composition consists essentially of betamethasone sodium phosphate at a concentration of 0.01% w/w to 0.05% w/w; mycophenolic acid at a concentration of 0.05% w/w to 0.50% w/w; and a pharmaceutically acceptable lubricating carrier for topical administration to the eye.

9 . A post-surgical ocular treatment method comprising: topically administering to an eye of a subject that has undergone ocular surgery, a therapeutically effective amount of the pharmaceutical composition of claim 1 .

10 . The method of claim 9 , wherein the pharmaceutical composition further comprises a chondroitin sulfate.

11 . The method of claim 10 , wherein the pharmaceutical composition further comprises dextran.

12 . The method of claim 9 , wherein the subject suffers from or is at risk of suffering from dry eye disease.

13 . A post-surgical ocular treatment method comprising: topically administering to an eye of a subject that has undergone ocular surgery, a therapeutically effective amount of the pharmaceutical composition of claim 8 .

14 . The method of claim 13 , wherein the subject suffers from or is at risk of suffering from dry eye disease.

15 . A post-surgical ocular treatment method comprising: topically administering to an eye of a subject that has undergone ocular surgery, a therapeutically effective amount of a pharmaceutical composition comprising betamethasone sodium phosphate at a concentration of 0.01% w/w to 0.05% w/w.

16 . The method of claim 15 , wherein the pharmaceutical composition consists essentially of the betamethasone sodium phosphate and a pharmaceutically acceptable lubricating carrier for topical administration to the eye.

17 . The method of claim 15 , wherein the subject suffers from or is at risk of suffering from dry eye disease.

18 . A method of treating dry eye disease, the method comprising: administering to a subject suffering from dry eye disease, a therapeutically effective amount of the pharmaceutical composition of claim 1 .

19 . The method of claim 18 , wherein the pharmaceutical composition further comprises a chondroitin sulfate.

20 . The method of claim 19 , wherein the pharmaceutical composition further comprises dextran.

21 . A method of treating dry eye disease, the method comprising: administering to a subject suffering from dry eye disease, a therapeutically effective amount of the pharmaceutical composition of claim 8 .

22 . A method of treating dry eye disease, the method comprising: administering to a subject suffering from dry eye disease, a therapeutically effective amount of a pharmaceutical composition comprising betamethasone sodium phosphate at a concentration of 0.01% w/w to 0.05% w/w.

23 . The method of claim 22 , wherein the pharmaceutical composition consists essentially of the betamethasone sodium phosphate and a pharmaceutically acceptable lubricating carrier for topical administration to the eye.

24 . A method of treating dry eye disease, the method comprising: administering to a subject suffering from dry eye disease, a therapeutically effective amount of a pharmaceutical composition comprising mycophenolic acid at a concentration of 0.05% w/w to 0.50 w/w.

25 . The method of claim 24 , wherein the pharmaceutical composition consists essentially of the mycophenolic acid and a pharmaceutically acceptable lubricating carrier for topical administration to the eye.